Suppr超能文献

心力衰竭中的心房颤动:导管及外科介入治疗

Atrial fibrillation in heart failure: catheter and surgical interventional therapies.

作者信息

Rabah Ali, Wazni Oussama

机构信息

Cleveland Clinic, 9500 Euclid Ave., Desk J2-2, Cleveland, OH, 44195, USA.

出版信息

Heart Fail Rev. 2014 May;19(3):325-30. doi: 10.1007/s10741-013-9411-x.

Abstract

Atrial fibrillation and heart failure commonly coexist in the same patient. Each may adversely affect the other. Atrial fibrillation leads to heart failure exacerbation, left ventricular function deterioration and an increase in thrombo-embolic risk. Therapeutic options targeting atrial fibrillation in heart failure patients include pharmacological and non-pharmacological means. Pharmacological therapy is directed at either rate control using nodal blocking agents or rhythm control using anti-arrhythmic agents, of which the options are limited in patients with heart failure. The landmark AF-CHF trial did not show any benefit of rhythm control strategy as opposed to rate control in patients with heart failure and atrial fibrillation. However, patients in this trial as well as in others used mostly amiodarone for rhythm control. This might have negated any positive effects of achieving normal sinus rhythm. Non-pharmacological therapy both for rate and rhythm control is appealing. This includes AV node ablation for rate control, catheter ablation of atrial fibrillation and surgical therapy of atrial fibrillation. This review will address non-pharmacologic treatment of AF in heart failure patients.

摘要

心房颤动和心力衰竭在同一患者中常同时存在。两者可能会相互产生不利影响。心房颤动会导致心力衰竭加重、左心室功能恶化以及血栓栓塞风险增加。针对心力衰竭患者心房颤动的治疗选择包括药物和非药物手段。药物治疗要么使用节点阻滞剂进行心率控制,要么使用抗心律失常药物进行节律控制,而对于心力衰竭患者,这些选择有限。具有里程碑意义的AF-CHF试验并未显示出在心力衰竭合并心房颤动患者中,节律控制策略相对于心率控制有任何益处。然而,该试验以及其他试验中的患者大多使用胺碘酮进行节律控制。这可能抵消了实现正常窦性心律的任何积极效果。用于心率和节律控制的非药物治疗很有吸引力。这包括用于心率控制的房室结消融、心房颤动导管消融和心房颤动手术治疗。本综述将探讨心力衰竭患者心房颤动的非药物治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验